Nxera Pharma Co., Ltd. Logo

Nxera Pharma Co., Ltd.

SOLTF

(2.0)
Stock Price

6,16 USD

-12.59% ROA

-5.51% ROE

-12.18x PER

Market Cap.

120.131.035.227,38 USD

97.32% DER

0% Yield

-12.68% NPM

Nxera Pharma Co., Ltd. Stock Analysis

Nxera Pharma Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Nxera Pharma Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (49%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

3 ROE

The stock's ROE falls within an average range (3.17%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (2.39%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 PBV

The stock's PBV ratio (1.77x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

6 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

7 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-13.328), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Nxera Pharma Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Nxera Pharma Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Nxera Pharma Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Nxera Pharma Co., Ltd. Revenue
Year Revenue Growth
2005 244.395.000
2006 415.501.000 41.18%
2007 739.777.000 43.83%
2008 709.122.000 -4.32%
2009 152.911.000 -363.75%
2010 919.684.000 83.37%
2011 716.573.000 -28.34%
2012 862.412.000 16.91%
2013 1.958.996.000 55.98%
2014 2.069.836.000 5.36%
2015 3.671.309.000 43.62%
2016 8.151.000.000 54.96%
2017 18.901.000.000 56.88%
2018 3.829.323.760 -393.59%
2019 9.726.000.000 60.63%
2020 8.842.000.000 -10%
2021 17.712.000.000 50.08%
2022 15.569.000.000 -13.76%
2023 13.312.000.000 -16.95%
2023 12.766.000.000 -4.28%
2024 32.436.000.000 60.64%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Nxera Pharma Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 385.000.000 100%
2013 305.000.000 -26.23%
2014 305.029.000 0.01%
2015 557.781.000 45.31%
2016 3.916.000.000 85.76%
2017 3.218.000.000 -21.69%
2018 7.178.648.720 55.17%
2019 4.292.000.000 -67.26%
2020 3.793.000.000 -13.16%
2021 5.931.000.000 36.05%
2022 7.454.000.000 20.43%
2023 11.896.000.000 37.34%
2023 10.075.000.000 -18.07%
2024 9.296.000.000 -8.38%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Nxera Pharma Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 1.984.708.000
2006 4.457.439.000 55.47%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 882.137.000 100%
2015 1.946.279.000 54.68%
2016 3.293.000.000 40.9%
2017 3.572.000.000 7.81%
2018 0 0%
2019 3.614.000.000 100%
2020 3.435.000.000 -5.21%
2021 3.940.000.000 12.82%
2022 4.377.000.000 9.98%
2023 13.764.000.000 68.2%
2023 9.965.000.000 -38.12%
2024 17.488.000.000 43.02%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Nxera Pharma Co., Ltd. EBITDA
Year EBITDA Growth
2005 -1.718.307.000
2006 -3.437.356.000 50.01%
2007 -5.016.234.000 31.48%
2008 -4.069.169.000 -23.27%
2009 -2.180.047.000 -86.66%
2010 -268.309.000 -712.51%
2011 -362.586.000 26%
2012 -353.230.000 -2.65%
2013 625.737.000 156.45%
2014 806.797.000 22.44%
2015 1.547.172.000 47.85%
2016 2.006.000.000 22.87%
2017 14.603.000.000 86.26%
2018 -6.030.651.590 342.15%
2019 2.516.000.000 339.69%
2020 3.550.000.000 29.13%
2021 5.302.000.000 33.04%
2022 5.015.000.000 -5.72%
2023 -10.656.000.000 147.06%
2023 -6.582.000.000 -61.9%
2024 464.000.000 1518.53%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Nxera Pharma Co., Ltd. Gross Profit
Year Gross Profit Growth
2005 231.345.000
2006 50.744.000 -355.91%
2007 249.266.000 79.64%
2008 586.788.000 57.52%
2009 31.364.000 -1770.9%
2010 791.980.000 96.04%
2011 665.929.000 -18.93%
2012 608.491.000 -9.44%
2013 1.633.247.000 62.74%
2014 1.818.435.000 10.18%
2015 3.602.980.000 49.53%
2016 8.147.000.000 55.78%
2017 18.901.000.000 56.9%
2018 2.011.994.970 -839.42%
2019 8.875.000.000 77.33%
2020 8.081.000.000 -9.83%
2021 16.779.000.000 51.84%
2022 14.643.000.000 -14.59%
2023 8.804.000.000 -66.32%
2023 7.866.000.000 -11.92%
2024 19.216.000.000 59.07%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Nxera Pharma Co., Ltd. Net Profit
Year Net Profit Growth
2005 -1.820.358.000
2006 -4.175.711.000 56.41%
2007 -6.239.512.000 33.08%
2008 -6.503.626.000 4.06%
2009 -3.938.646.000 -65.12%
2010 -1.769.167.000 -122.63%
2011 -1.871.882.000 5.49%
2012 -1.954.389.000 4.22%
2013 -646.856.000 -202.14%
2014 1.526.177.000 142.38%
2015 562.522.000 -171.31%
2016 -1.547.000.000 136.36%
2017 9.638.000.000 116.05%
2018 -7.947.313.630 221.27%
2019 1.432.000.000 654.98%
2020 1.479.000.000 3.18%
2021 1.017.000.000 -45.43%
2022 382.000.000 -166.23%
2023 -19.700.000.000 101.94%
2023 -7.193.000.000 -173.88%
2024 -5.688.000.000 -26.46%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Nxera Pharma Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 -80
2006 -126 36%
2007 -155 18.83%
2008 -138 -11.59%
2009 -84 -66.27%
2010 -38 -124.32%
2011 -40 5.13%
2012 -41 4.88%
2013 -14 -215.38%
2014 32 141.94%
2015 10 -210%
2016 -25 140%
2017 143 117.61%
2018 -104 236.54%
2019 19 677.78%
2020 19 0%
2021 13 -50%
2022 5 -200%
2023 -239 101.67%
2023 -87 -174.71%
2024 -63 -38.1%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Nxera Pharma Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2005 -1.725.719.000
2006 -3.207.198.000 46.19%
2007 -4.298.139.000 25.38%
2008 -4.011.809.000 -7.14%
2009 -2.987.307.000 -34.3%
2010 16.745.000 17939.99%
2011 -96.223.000 117.4%
2012 -561.492.000 82.86%
2013 799.805.000 170.2%
2014 352.758.000 -126.73%
2015 3.680.000 -9485.82%
2016 4.341.000.000 99.92%
2017 12.524.000.000 65.34%
2018 -3.047.000.000 511.03%
2019 3.161.000.000 196.39%
2020 4.567.000.000 30.79%
2021 6.894.000.000 33.75%
2022 9.649.000.000 28.55%
2023 -6.124.000.000 257.56%
2023 -1.767.000.000 -246.58%
2024 3.660.000.000 148.28%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Nxera Pharma Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2005 -1.700.784.000
2006 -3.190.478.000 46.69%
2007 -4.181.499.000 23.7%
2008 -3.949.608.000 -5.87%
2009 -2.986.214.000 -32.26%
2010 32.061.000 9414.16%
2011 -89.120.000 135.98%
2012 -286.846.000 68.93%
2013 828.173.000 134.64%
2014 363.279.000 -127.97%
2015 92.570.000 -292.44%
2016 4.471.000.000 97.93%
2017 12.856.000.000 65.22%
2018 -2.167.000.000 693.26%
2019 3.441.000.000 162.98%
2020 4.672.000.000 26.35%
2021 7.095.000.000 34.15%
2022 9.952.000.000 28.71%
2023 -5.273.000.000 288.74%
2023 -1.466.000.000 -259.69%
2024 3.716.000.000 139.45%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Nxera Pharma Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2005 24.935.000
2006 16.720.000 -49.13%
2007 116.640.000 85.67%
2008 62.201.000 -87.52%
2009 1.093.000 -5590.85%
2010 15.316.000 92.86%
2011 7.103.000 -115.63%
2012 274.646.000 97.41%
2013 28.368.000 -868.15%
2014 10.521.000 -169.63%
2015 88.890.000 88.16%
2016 130.000.000 31.62%
2017 332.000.000 60.84%
2018 880.000.000 62.27%
2019 280.000.000 -214.29%
2020 105.000.000 -166.67%
2021 201.000.000 47.76%
2022 303.000.000 33.66%
2023 851.000.000 64.39%
2023 301.000.000 -182.72%
2024 56.000.000 -437.5%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Nxera Pharma Co., Ltd. Equity
Year Equity Growth
2005 9.726.388.000
2006 24.475.989.000 60.26%
2007 21.282.444.000 -15.01%
2008 15.782.400.000 -34.85%
2009 12.138.320.000 -30.02%
2010 10.376.819.000 -16.98%
2011 8.656.450.000 -19.87%
2012 7.102.229.000 -21.88%
2013 6.511.826.000 -9.07%
2014 14.595.998.000 55.39%
2015 14.894.690.000 2.01%
2016 23.268.000.000 35.99%
2017 28.845.000.000 19.33%
2018 48.886.000.000 41%
2019 45.078.000.000 -8.45%
2020 52.381.000.000 13.94%
2021 57.468.000.000 8.85%
2022 57.936.000.000 0.81%
2023 66.810.000.000 13.28%
2023 57.954.000.000 -15.28%
2024 68.980.000.000 15.98%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Nxera Pharma Co., Ltd. Assets
Year Assets Growth
2005 9.879.715.000
2006 25.307.235.000 60.96%
2007 23.193.765.000 -9.11%
2008 17.403.824.000 -33.27%
2009 12.367.045.000 -40.73%
2010 10.673.098.000 -15.87%
2011 8.991.787.000 -18.7%
2012 7.390.340.000 -21.67%
2013 6.794.785.000 -8.76%
2014 14.582.280.000 53.4%
2015 43.800.862.000 66.71%
2016 47.354.000.000 7.5%
2017 48.087.000.000 1.52%
2018 69.486.000.000 30.8%
2019 56.680.000.000 -22.59%
2020 76.465.000.000 25.87%
2021 96.985.000.000 21.16%
2022 99.417.000.000 2.45%
2023 157.198.000.000 36.76%
2023 149.439.000.000 -5.19%
2024 156.484.000.000 4.5%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Nxera Pharma Co., Ltd. Liabilities
Year Liabilities Growth
2005 153.327.000
2006 831.246.000 81.55%
2007 1.911.321.000 56.51%
2008 1.621.424.000 -17.88%
2009 228.725.000 -608.9%
2010 296.279.000 22.8%
2011 335.337.000 11.65%
2012 288.111.000 -16.39%
2013 282.959.000 -1.82%
2014 227.282.000 -24.5%
2015 28.906.172.000 99.21%
2016 24.086.000.000 -20.01%
2017 19.242.000.000 -25.17%
2018 20.600.000.000 6.59%
2019 11.602.000.000 -77.56%
2020 24.084.000.000 51.83%
2021 39.517.000.000 39.05%
2022 41.481.000.000 4.73%
2023 90.388.000.000 54.11%
2023 91.485.000.000 1.2%
2024 87.504.000.000 -4.55%

Nxera Pharma Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
260.27
Net Income per Share
-109.68
Price to Earning Ratio
-12.18x
Price To Sales Ratio
5.15x
POCF Ratio
-153.23
PFCF Ratio
-78.72
Price to Book Ratio
1.74
EV to Sales
6.01
EV Over EBITDA
-25.69
EV to Operating CashFlow
-179.31
EV to FreeCashFlow
-91.89
Earnings Yield
-0.08
FreeCashFlow Yield
-0.01
Market Cap
120,13 Bil.
Enterprise Value
140,22 Bil.
Graham Number
1377.8
Graham NetNet
-321.69

Income Statement Metrics

Net Income per Share
-109.68
Income Quality
0.09
ROE
-0.15
Return On Assets
-0.02
Return On Capital Employed
-0.04
Net Income per EBT
0.73
EBT Per Ebit
0.98
Ebit per Revenue
-0.18
Effective Tax Rate
0.27

Margins

Sales, General, & Administrative to Revenue
0.66
Research & Developement to Revenue
0.49
Stock Based Compensation to Revenue
0.05
Gross Profit Margin
0.62
Operating Profit Margin
-0.18
Pretax Profit Margin
-0.17
Net Profit Margin
-0.13

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-8.72
Free CashFlow per Share
-17.02
Capex to Operating CashFlow
-0.95
Capex to Revenue
0.03
Capex to Depreciation
0.2
Return on Invested Capital
-0.07
Return on Tangible Assets
-0.13
Days Sales Outstanding
135.85
Days Payables Outstanding
156.33
Days of Inventory on Hand
92.54
Receivables Turnover
2.69
Payables Turnover
2.33
Inventory Turnover
3.94
Capex per Share
8.3

Balance Sheet

Cash per Share
568,53
Book Value per Share
769,21
Tangible Book Value per Share
-104.55
Shareholders Equity per Share
769.21
Interest Debt per Share
778.25
Debt to Equity
0.97
Debt to Assets
0.43
Net Debt to EBITDA
-3.68
Current Ratio
4.11
Tangible Asset Value
-9,38 Bil.
Net Current Asset Value
-23,86 Bil.
Invested Capital
134429000000
Working Capital
48,14 Bil.
Intangibles to Total Assets
0.5
Average Receivables
7,39 Bil.
Average Payables
3,50 Bil.
Average Inventory
2200000000
Debt to Market Cap
0.56

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Nxera Pharma Co., Ltd. Dividends
Year Dividends Growth
2015 10

Nxera Pharma Co., Ltd. Profile

About Nxera Pharma Co., Ltd.

Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.

CEO
Mr. Christopher Cargill
Employee
372
Address
PMO Hanzomon
Tokyo, 102-0083

Nxera Pharma Co., Ltd. Executives & BODs

Nxera Pharma Co., Ltd. Executives & BODs
# Name Age
1 Mr. Shinichiro Nishishita
Vice President of Investor Relations & Head of Regulatory Disclosures
70
2 Ms. Candelle Chong
Executive Officer, Executive Vice President, Chief Executive Officer Office & Chief of Staff
70
3 Mr. Christopher Cargill
Representative Executive Officer, President, Chief Executive Officer & Director
70
4 Mr. Toshihiro Maeda
Executive Vice President & Chief Operating Officer
70
5 Mr. Kazuhiko Yoshizumi
Executive Officer, Executive Vice President & Chief Compliance Officer
70
6 Stacey Southall
Associate Director & Head of Biophysics
70
7 Mr. Patrick Branch
Head of Business Development for Japan and the APAC region
70
8 Dr. Shinichi Tamura
Founder & Chairman of the Board
70
9 Mr. Kieran Johnson F.C.A.
Executive Officer, Executive Vice President & Chief Accounting Officer
70
10 Mr. Hironoshin Nomura
Executive Officer, Executive Vice President & Chief Financial Officer
70

Nxera Pharma Co., Ltd. Competitors